Cholesterol and Statins — A Plain-English Summary

What this is

A long, careful read of what the science actually says about cholesterol, statins, and the long argument about whether they help, harm, or both. Long enough to be useful (roughly 250 pages), short enough that the headline conclusions fit on a single page. This is the headline-page version.

Who it's for

Anyone who's been told to take a statin and isn't sure; anyone who's read on social media that the whole thing is a scam and isn't sure about that either; anyone who wants to understand what their GP is weighing up when they hand over the prescription, or what their cardiologist is reading when they don't. It is not medical advice. It is a map of what is settled, what is genuinely disputed, and where the evidence actually sits underneath the headlines.

The three things you need to know

One. The biology is real. LDL — what people call "bad cholesterol" — is not just a marker. It causes heart disease. The strongest evidence for this isn't actually the drug trials; it's the genetics. People born with genetic variants that give them lifelong low LDL almost never get coronary heart disease. People born with genetic variants that give them lifelong high LDL (familial hypercholesterolaemia) often have heart attacks in their forties unless treated. This is not the contested claim, and it's worth understanding because almost every argument you read online starts by quietly denying it.

Two. Statins work — but how much they work depends entirely on who's taking them. If you've already had a heart attack, statins meaningfully reduce your chance of another one and probably extend your life. The evidence here is overwhelming and it's not seriously disputed by anyone who's read the studies. If you have a strong family history of early heart disease, the case is also strong. If you're 50, otherwise healthy, with cholesterol slightly above average and no other risk factors, the absolute benefit is genuinely small — measured in single percentage points over five years — and reasonable people can disagree about whether it's worth taking a daily pill for that benefit. The argument isn't really about whether statins work. It's about whether the benefit is worth it for low-risk people. Most public conversations don't make this distinction, which is why most public conversations go in circles.

Three. The side effects are largely (not entirely) in the mind — but they are real. This is the most surprising finding to most people. A trial called SAMSON in 2020 put people who said statins were giving them muscle pain through a clever crossover design where they took the statin, a placebo, and no tablet at all in different months without knowing which was which. They got muscle pain in all three months at roughly equal rates. About 90% of the symptom intensity was attributed to nocebo (the opposite of placebo — expecting a drug to harm you actually produces harm). About 10% was specifically the drug. This doesn't mean nobody has real statin side effects. Some people do — there's a genetic variant called SLCO1B1 that genuinely predisposes to muscle problems with one particular statin. But the vast majority of complaints in routine practice are not specifically the drug. The clinical implication is that if you stop a statin because of muscle pain, the right next step is to try a different one at a lower dose before giving up on the class entirely.

The thing the document does that most public conversations don't

It separates the things that are settled from the things that are genuinely contested. Public arguments tend to mash everything together — pro-statin people defend every prescription as if low-risk primary prevention were as well-supported as familial hypercholesterolaemia (it isn't); anti-statin people dismiss the whole drug class as if secondary prevention were as thin as the elderly-healthy data (it isn't). The honest answer is in the middle, and it changes substantially depending on what kind of patient you are.

Settled and not seriously disputed: - LDL causes heart disease - Statins help people who've had heart attacks - Statins help people with familial hypercholesterolaemia - Statins help people with diabetes plus other risk factors - The CETP inhibitors (the "raise good cholesterol" drugs) don't work

Genuinely contested: - Whether to give statins routinely to low-risk healthy adults under 75 - Whether to give statins to healthy adults over 75 (two huge trials, STAREE and PREVENTABLE, will substantially answer this in late 2025 and December 2026) - Whether the benefits in women without prior heart disease are large enough to justify routine prescription - How much of the muscle-pain complaint is real and how much is expectation - Whether industry-funded trials are reliable in their detail (the meta-finding survives, but specific trials have demonstrably been distorted)

Pharmaceutical industry conflicts of interest, honestly: - Yes, they exist. ENHANCE (an ezetimibe trial) had its publication delayed when results came back disappointing. JUPITER (rosuvastatin) was stopped early in a way that probably overstated benefit. Vioxx (a different drug) is the cautionary tale for what happens when industry controls the data and the analysis. - And yet: the core finding that LDL lowering reduces cardiovascular events survives this critique because it's been confirmed by genetics (which can't be corrupted by industry), by investigator-initiated trials, by generic post-patent statins (no commercial incentive to maintain the consensus), and by four mechanistically distinct drug classes hitting the same target. - The mature position is to take the industry critique seriously while not letting it dismiss the core finding. The drugs work and the industry has demonstrably misbehaved on specific occasions. Both can be true.

The honest one-sentence position

The case for statin therapy is overwhelming if you've already had a heart attack, if you have familial hypercholesterolaemia, or if you're at high primary-prevention risk. The case is empirically thinner and ethically more contestable if you're a low-risk healthy adult, particularly if you're an older woman with no other risk factors, and the conversation in that case should be a shared decision with a clinician who knows your specific numbers — not a decision driven by a population-level guideline.

That sentence will frustrate partisans on both sides. That's the point. The truth on contested medical questions almost never looks like the headlines.

What's coming

Two trials in the next eighteen months will substantially change this conversation. STAREE (Australian, atorvastatin in 9,971 healthy adults over 70) reads out in late 2025. PREVENTABLE (American, atorvastatin in 20,000 healthy adults over 75, with the primary endpoint being not just heart attacks but survival free of dementia and disability) reads out in December 2026. If both come back positive, the case for statin therapy in the elderly becomes much clearer. If both come back negative, the public conversation will and should shift substantially. Either way, you'll know more then than you do now.

The Lp(a) story is also moving fast. Lp(a) is a particularly nasty kind of cholesterol-carrying particle that about 20% of people inherit elevated levels of, and standard statins don't help much. Three new drugs (pelacarsen, olpasiran, lepodisiran) reduce Lp(a) by 80–94%; outcome trials read out between mid-2025 and 2027. If they work, this becomes a meaningful new option for a population currently underserved.

How to use the long document

If you only have ten minutes, the chapter to read is Chapter 34 (the calibrated landing position). If you have an hour, add Chapter 32 (Bradford-Hill applied), Chapter 33 (the NNT/NNH table by patient type), and the eight myths in Chapter 31. If you're going into a real conversation with a clinician or someone who works in the industry, also read the debate playbook in Appendix A — eight conversation-ready cards for the actual exchange.

A note on epistemic honesty

The full document doesn't try to tell you what to do. It tries to give you what you need to decide what to do for yourself, in conversation with a clinician who knows you. That distinction matters. Anyone who tells you the cholesterol question has a single right answer for everyone hasn't read the evidence carefully enough, or doesn't trust you with it.